131 related articles for article (PubMed ID: 16965395)
21. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
[TBL] [Abstract][Full Text] [Related]
22. Possible distinct molecular carcinogenic pathways for bladder cancer in Ukraine, before and after the Chernobyl disaster.
Morimura K; Romanenko A; Min W; Salim EI; Kinoshita A; Wanibuchi H; Vozianov A; Fukushima S
Oncol Rep; 2004 Apr; 11(4):881-6. PubMed ID: 15010889
[TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Iyer G; Milowsky MI
Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
[TBL] [Abstract][Full Text] [Related]
24. Urothelial carcinoma of the bladder in patients aged 30 years or younger: clinicopathological analysis and expression of fibroblast growth factor receptor 3 (FGFR3) of 45 cases.
Huang H; Sun M; Li X; Jin J
Med Oncol; 2015 May; 32(5):137. PubMed ID: 25801230
[TBL] [Abstract][Full Text] [Related]
25. Complexity of FGFR signalling in metastatic urothelial cancer.
Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
[TBL] [Abstract][Full Text] [Related]
26. [Recent advances in diagnosis of flat lesions of urinary bladder].
Cheng L; Xu JW; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):577-81. PubMed ID: 21092582
[No Abstract] [Full Text] [Related]
27. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
28. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder.
Sun W; Zhang PL; Herrera GA
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):327-31. PubMed ID: 12607601
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors.
Hernández S; Toll A; Baselga E; Ribé A; Azua-Romeo J; Pujol RM; Real FX
J Invest Dermatol; 2007 Jul; 127(7):1664-6. PubMed ID: 17255960
[TBL] [Abstract][Full Text] [Related]
30. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
31. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa.
Palmeira C; Lameiras C; Amaro T; Lima L; Koch A; Lopes C; Oliveira PA; Santos L
Urol Oncol; 2011; 29(2):205-11. PubMed ID: 19854077
[TBL] [Abstract][Full Text] [Related]
32. p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions.
Kamel D; Soini Y; Nuorva K; Khalifa A; Mangoud A; Vähäkangas K; Pääkkö P
Virchows Arch; 1994; 424(4):349-55. PubMed ID: 7911381
[TBL] [Abstract][Full Text] [Related]
33. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
[TBL] [Abstract][Full Text] [Related]
34. [Development of invasive urinary bladder carcinomas].
Fukushima S; Wanibuchi H; Wei M; Morimura K
Hinyokika Kiyo; 2006 Jun; 52(6):451-5. PubMed ID: 16848359
[TBL] [Abstract][Full Text] [Related]
35. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
[TBL] [Abstract][Full Text] [Related]
36. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
37. Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia.
Lane Z; Epstein JI
Am J Surg Pathol; 2008 May; 32(5):758-64. PubMed ID: 18379418
[TBL] [Abstract][Full Text] [Related]
38. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
Mai KT; Busca A; Belanger EC
Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
[TBL] [Abstract][Full Text] [Related]
39. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
40. Urothelial Carcinoma In Situ of the Bladder With Glandular Differentiation: Report of 92 Cases.
Yang Z; Epstein JI
Am J Surg Pathol; 2018 Jul; 42(7):971-976. PubMed ID: 29683821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
